Clinical trials: Myelodysplastic Syndrome
Myelodysplastic Syndromes
Survey on QUality of Life In myeloDisplasia (SQUID)
The purpose of this study is to evaluate the correlation between quality of life (QoL) and hemoglobin in patients affected by myelodysplastic syndrome and to compare the MDS (MyeloDisplastic Syndrome) patient's self-assessed QoL…
- Trial name
- NCT00967564
- Testing
- epidemiologic study
- Volunteers
- 160 people
- Sponsor
- Janssen-Cilag S.p.A.
Myelodysplastic Syndromes
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
The study is to evaluate safety and efficacy of IBI188 in combination with azacitidine (AZA) as a first-line treatment in subjects with newly diagnosed higher risk myelodysplastic syndrome
- Trial name
- NCT04485065
- Testing
- IBI188+azacitidine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia (AML)
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
There was no well accepted standard of care for participants who failed or were intolerant to any of the currently approved therapies for myelodysplastic syndromes (MDS).
- Trial name
- NCT00531232
- Testing
- Clofarabine
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Genzyme, a Sanofi Company
Iron Deficiency Anemia
A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).
This study aims to explore the safety and preliminary efficacy of a response-guided dose titration of KER-047 in the treatment of functional IDA (Iron deficiency anemia) in MDS (Myelodysplastic syndrome), MF(Myelofibrosis), and…
- Trial name
- NCT05927012
- Testing
- KER-047
- Where
- 5 sites in Australia, Israel
- Sponsor
- Keros Therapeutics, Inc.
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486, known as oral azacitidine, in patients with AML or MDS after allogeneic hematopoetic stem cell transplant (HSCT).
- Trial name
- NCT01835587
- Testing
- CC-486
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Celgene
Solid Tumors, Hematologic Malignancies
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors.
- Conditions
- Solid Tumors, Hematologic Malignancies, Myelodysplastic Syndrome
- Trial name
- NCT00741234
- Testing
- SB939, Azacitidine
- Where
- 5 sites in United States, Singapore
- Volunteers
- 85 people
- Sponsor
- S*BIO
Myelodysplastic Syndrome
A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
The purpose of this study is to determine the effectiveness and safety of two different dose schedules of DACOGEN® (decitabine) for Injection in patients with Myelodysplastic Syndromes (MDS).
- Trial name
- NCT00619099
- Testing
- decitabine
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- Eisai Inc.
Leukemia, Myelodysplastic Syndromes
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00083187
- Testing
- hydroxyurea, laromustine
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 230 people
- Sponsor
- Vion Pharmaceuticals
Myelodysplastic Syndrome (MDS)
Patient Reported Outcomes and Patient Voice Among Patients Diagnosed With Low Risk Myelodysplastic Syndrome (LR-MDS) or Unexplained Anemia In Japan
This study will examine quality of life, experiences, and unmet needs among individuals diagnosed with Low Risk Myelodysplastic Syndrome who are erythropoietin stimulating agent naïve and non-transfusion dependent and among…
- Trial name
- NCT07008820
- Testing
- Health-related quality of life questionnaires, Qualitative interviews
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Bristol-Myers Squibb
Myelodysplastic Syndromes, Blood Disease
Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
This study is to evaluate the efficacy, safety and tolerability of vorinostat in patients with lower risk Myelodysplastic Syndrome (MDS).
- Conditions
- Myelodysplastic Syndromes, Blood Disease, Bone Marrow Disease
- Trial name
- NCT00486720
- Testing
- vorinostat
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Paroxysmal Nocturnal Hemoglobinuria
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
- Trial name
- PRIORITY- PNH (NCT07036718)
- Where
- 5 sites in Russia
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndrome
A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome
The purpose of this study is to evaluate the effectiveness and safety of decitabine (Dacogen) intravenous injection in patients with Myelodysplastic Syndrome.
- Trial name
- NCT01041846
- Testing
- No intervention
- Volunteers
- 103 people
- Sponsor
- Janssen Korea, Ltd., Korea
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced myeloid malignancies. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread…
- Trial name
- NCT01606579
- Testing
- PRI-724
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Prism Pharma Co., Ltd.
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes
A Phase 1, an Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 (RVT-2001) for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
- Trial name
- Encore-MDS (NCT02841540)
- Testing
- H3B-8800 (RVT-2001)
- Where
- 49 sites in United States, Belgium and 5 more
- Volunteers
- 127 people
- Sponsor
- Hemavant Sciences GmbH
Paroxysmal Nocturnal Hemoglobinuria
A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
This is a single-arm long-term extension study that will enroll participants with PNH who have completed participation in Alexion-sponsored clinical studies with danicopan as an add on therapy to a C5i.
- Trial name
- NCT05389449
- Testing
- Danicopan
- Where
- 45 sites in United States, Brazil and 13 more
- Volunteers
- 80 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Myelodysplastic Syndrome (MDS)
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
This is a clinical trial to determine the safety, recommended dose level (RDL), and infection control of BLEX 404 Oral Liquid in combination with azacitidine in patients with International Prognostic Scoring System (IPSS)…
- Trial name
- NCT02944955
- Testing
- BLEX 404 Oral Liquid
- Volunteers
- 52 people
- Sponsor
- BioLite, Inc.
Beta-thalassemia, Myelodysplastic Syndromes
Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
The purpose of this study is to determine the effects of the oral iron chelator Deferasirox on liver iron content after one year of treatment in patients with iron overload from repeated blood transfusions.
- Conditions
- Beta-thalassemia, Myelodysplastic Syndromes, Fanconi Syndrome, Anemia, Diamond-Blackfan
- Trial name
- NCT00061763
- Testing
- Deferasirox
- Where
- 6 sites in United States
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndromes
Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes
This study is a multi-center, single-arm, open-label study of oral CC-5013 monotherapy administered at a dose of 10 mg daily on Days 1-21 every 28 days (28-day cycles) to red blood cell (RBC) transfusion-dependent subjects with…
- Trial name
- NCT00064974
- Testing
- CC-5013
- Where
- 119 sites in United States, Australia and 13 more
- Volunteers
- 215 people
- Sponsor
- Celgene Corporation
Myelodysplastic Syndromes
Expanded Access for Treatment With Imetelstat
The objective of this expanded access protocol (EAP) is to provide access to treatment with imetelstat, the Investigational Product (IP), for eligible adult participants diagnosed with very low, low, intermediate risk (by Revised…
- Trial name
- NCT05937568
- Testing
- Imetelstat
- Sponsor
- Geron Corporation
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams…
- Trial name
- NCT04953910
- Testing
- ASTX727
- Where
- 22 sites in United States, Armenia and 6 more
- Volunteers
- 27 people
- Sponsor
- Taiho Oncology, Inc.